GRTX
Income statement / Annual
Last year (2023), Galera Therapeutics, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2023, Galera Therapeutics, Inc.'s net income was -$59.08 M.
See Galera Therapeutics, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
| Operating Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Cost of Revenue |
$259,000.00 |
$114,000.00 |
$778,000.00 |
$368,000.00 |
$267,000.00 |
$127,000.00 |
$84,000.00 |
| Gross Profit |
-$259,000.00 |
-$114,000.00 |
-$778,000.00 |
-$368,000.00 |
-$267,000.00 |
-$127,000.00 |
-$84,000.00 |
| Gross Profit Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
| Research and Development
Expenses |
$24.12 M
|
$31.01 M
|
$52.42 M
|
$54.85 M
|
$42.33 M
|
$18.66 M
|
$20.59 M
|
| General & Administrative
Expenses |
$22.84 M
|
$20.21 M
|
$20.95 M
|
$15.71 M
|
$8.36 M
|
$5.59 M
|
$3.50 M
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$22.84 M
|
$20.21 M
|
$20.95 M
|
$15.71 M
|
$8.36 M
|
$5.59 M
|
$3.50 M
|
| Other Expenses |
$0.00 |
-$11.07 M |
-$7.17 M |
-$3.68 M |
-$1.25 M |
$0.00 |
$0.00 |
| Operating Expenses |
$46.95 M |
$51.23 M |
$73.37 M |
$70.55 M |
$50.69 M |
$24.26 M |
$24.09 M |
| Cost And Expenses |
$46.95 M |
$51.23 M |
$73.37 M |
$70.55 M |
$50.69 M |
$24.26 M |
$24.09 M |
| Interest Income |
$9.82 M |
$506,000.00 |
$32,000.00 |
$1.17 M |
$1.82 M |
$606,000.00 |
$193,000.00 |
| Interest Expense |
$0.00 |
$11.57 M |
$7.19 M |
$4.88 M |
$3.03 M |
$220,000.00 |
$0.00 |
| Depreciation &
Amortization |
$259,000.00
|
$114,000.00
|
$778,000.00
|
$368,000.00
|
$267,000.00
|
$127,000.00
|
$84,000.00
|
| EBITDA |
-$46.69 M
|
-$50.61 M
|
-$72.56 M
|
-$69.01 M
|
-$50.69 M
|
-$23.52 M
|
-$23.82 M
|
| EBITDA Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
| Operating Income Ratio
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other
Income/Expenses Net |
-$12.13 M
|
-$11.07 M
|
-$7.17 M
|
-$3.68 M
|
-$1.25 M
|
$356,000.00
|
$189,000.00
|
| Income Before Tax |
-$59.08 M |
-$62.29 M |
-$80.53 M |
-$74.23 M |
-$51.94 M |
-$23.90 M |
-$23.91 M |
| Income Before Tax Ratio
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00 |
-$70,000.00 |
$7.19 M |
-$16,000.00 |
-$9,000.00 |
-$223,000.00 |
-$360,000.00 |
| Net Income |
-$59.08 M |
-$62.22 M |
-$87.73 M |
-$74.22 M |
-$51.93 M |
-$23.68 M |
-$23.55 M |
| Net Income Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
| EPS |
-1.33 |
-2.3 |
-3.4 |
-2.98 |
-2.09 |
-1.22 |
-1.55 |
| EPS Diluted |
-1.33 |
-2.3 |
-3.4 |
-2.98 |
-2.09 |
-1.22 |
-1.55 |
| Weighted Average Shares
Out |
$44.55 M
|
$27.09 M
|
$25.79 M
|
$24.87 M
|
$24.81 M
|
$19.36 M
|
$15.22 M
|
| Weighted Average Shares
Out Diluted |
$44.55 M
|
$27.09 M
|
$25.79 M
|
$24.87 M
|
$24.81 M
|
$19.36 M
|
$15.22 M
|
| Link |
|
|
|
|
|
|
|
